Related Experiment Video
Updated: May 19, 2026
Pentylenetetrazole-Induced Kindling Mouse Model
Published on: June 12, 2018
Anti-epileptic and Neuroprotective Effects of Ultra-low Dose NADPH Oxidase Inhibitor Dextromethorphan on Kainic
Jing-Jing Yang1,2,3, Ying-Xin Liu1,3, Yan-Fang Wang1,3
1College of Basic Medical Sciences, Dalian Medical University, Dalian, 116044, China.
Abstract:
Neuroinflammation mediated by microglia and oxidative stress play pivotal roles in the development of chronic temporal lobe epilepsy (TLE). We postulated that kainic acid (KA)-Induced status epilepticus triggers microglia-dependent inflammation, leading to neuronal damage, a lowered seizure threshold, and the emergence of spontaneous recurrent seizures (SRS). Extensive evidence from our laboratory suggests that dextromethorphan (DM), even in ultra-low doses, has anti-inflammatory and neuroprotective effects in many animal models of neurodegenerative disease. Our results showed that administration of DM (10 ng/kg per day; subcutaneously via osmotic minipump for 4 weeks) significantly mitigated the residual effects of KA, including the frequency of SRS and seizure susceptibility. In addition, DM-treated rats showed improved cognitive function and reduced hippocampal neuronal loss. We found suppressed microglial activation-mediated neuroinflammation and decreased expression of hippocampal gp91phox and p47phox proteins in KA-induced chronic TLE rats. Notably, even after discontinuation of DM treatment, ultra-low doses of DM continued to confer long-term anti-seizure and neuroprotective effects, which were attributed to the inhibition of microglial NADPH oxidase 2 as revealed by mechanistic studies.
Insights
Dextromethorphan (DM) in ultra-low doses reduces inflammation and neuronal damage in epilepsy models. This treatment lowers seizure frequency and susceptibility, offering long-term neuroprotection by inhibiting microglial activation.
Area of Science:
- Neuroscience
- Pharmacology
- Epilepsy Research
Background:
- Neuroinflammation and oxidative stress are key factors in chronic temporal lobe epilepsy (TLE).
- Kainic acid (KA)-induced seizures trigger microglial activation, leading to neuronal damage and epilepsy.
- Dextromethorphan (DM) exhibits anti-inflammatory and neuroprotective properties in neurodegenerative models.
Purpose of the Study:
- To investigate the efficacy of ultra-low dose dextromethorphan (DM) in mitigating chronic epilepsy.
- To explore DM's effects on neuroinflammation, neuronal loss, and seizure activity in a kainic acid (KA) epilepsy model.
Main Methods:
- Rats received KA to induce status epilepticus, followed by subcutaneous DM administration (10 ng/kg/day) for 4 weeks.
- Evaluated seizure frequency, seizure susceptibility, cognitive function, and hippocampal neuronal loss.
- Assessed microglial activation, neuroinflammation markers, and NADPH oxidase (gp91phox, p47phox) expression.
Main Results:
- DM treatment significantly reduced spontaneous recurrent seizures (SRS) frequency and seizure susceptibility.
- DM administration improved cognitive function and decreased hippocampal neuronal loss.
- Suppressed microglial activation, reduced neuroinflammation, and decreased gp91phox/p47phox expression were observed in DM-treated rats.
- Long-term anti-seizure and neuroprotective effects persisted after DM discontinuation, linked to microglial NADPH oxidase 2 inhibition.
Conclusions:
- Ultra-low dose DM demonstrates significant anti-seizure and neuroprotective effects in chronic TLE.
- DM mitigates epilepsy by suppressing microglial activation and neuroinflammation.
- The findings suggest a novel therapeutic potential for DM in managing chronic epilepsy.
